natgillin/translations-raw huggingface dataset:
Unusual bruising or bleeding, sometimes severe, caused by a decrease in the number of blood clotting cells (platelets).
Nenavadne podplutbe ali krvavitve, ki so včasih hude in so posledica zmanjšanega števila krvnih ploščic (trombocitov), potrebnih za strjevanje krvi.
Unusual bruising or bleeding, sometimes severe, caused by a decrease in the number of blood clotting cells (platelets).
Neobičajne modrice ali krvavitve (včasih v hujši obliki), ki so posledica zmanjšanja števila trombocitov (krvnih ploščic).
Unusual bruising or bleeding, such as a cut, that takes longer than usual to stop bleeding; or internal bleeding such as coughing up blood, vomiting up blood, dark tarry stools, or bright red blood in your stools; or bleeding in the brain leading to sudden numbness or paralysis on one side of the face, legs or arms, sudden severe headache or trouble seeing or difficulty speaking or swallowing
Neobičajne podplutbe ali krvavitve, kot je vrezna rana, pri kateri ustavitev krvavitve traja dlje kot pričakovano; ali notranje krvavitve, kot je izkašljevanje krvi, kri v izbruhani vsebini, temno, smolasto blato ali svetlo rdeča kri v blatu; ali krvavitev v možgane, ki povzroči nenadno omrtvičenost ali ohromelost na eni strani obraza, eni roki ali eni nogi, nenaden hud glavobol ali težave z vidom ali težave z govorjenjem ali požiranjem.
unusual bruising, nosebleeds, bleeding of gums, cuts that take a long time to stop bleeding
neobičajne modrice, krvavitev iz nosu, krvavitev iz dlesni, ureznine, pri katerih dolgo traja, da se krvavitev ustavi
unusual change in the urine
neobičajne spremembe urina
unusual change in the urine
neobičajne spremembe v urinu
unusual change in urine
neobičajne spremembe urina
unusual crying
nenavaden jok
unusual crying
neobičajno jokanje
unusual crying feeling irritable or restless
nenavadno jokanje, občutek razdražljivosti ali nemirnosti.
unusual crying feeling irritable or restless
nenavadno jokanje, občutek razdražljivosti in nemirnosti.
unusual crying feeling irritable or restless.
nenavadno jokanje, občutek razdražljivosti ali nemirnosti.
unusual difficulty in breathing with wheezing or coughing, chest tightness
neobičajno oteženo dihanje s piskanjem ali kašljem in z občutkom stiskanja v prsih,
Unusual dreams or nightmares
neobičajne sanje ali nočne more
unusual dreams sleepiness
neobičajne sanje, zaspanost.
unusual feelings of the skin – such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch
neobičajni občutki na koži – na primer omrtvičenost, mravljinčenje, zbadanje, pekoč občutek, občutek gomazenja na koži, slabše zaznavanje dotika
unusual feelings of the skin – such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch
neobičajni občutki na koži – na primer omrtvičenost, mravljinčenje, zbadanje, pekoč občutek, občutek gomazenja na koži, slabše zaznavanje dotika,
Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
Redko se lahko pojavi nenavaden zlom stegnenice, predvsem pri bolnikih, ki dolgotrajno prejemajo zdravljenje za osteoporozo.
Unusual fractures of the thigh bone may occur rarely.
Redko se lahko pojavijo neobičajni zlomi stegnenice.
Unusual hair loss
nenavadno izpadanje las,
Unusual hair loss or thinning
nenavadno izpadanje ali razredčenje las
unusual hair loss or thinning
neobičajno izpadanje ali redčenje las
unusual hair loss or thinning
neobičajno izpadanje ali redčenje las,
Unusual hair loss or thinning
neobičajno izpadanje ali tanjšanje las
unusual hair loss or thinning (alopecia)
neobičajno izpadanje ali redčenje las (alopecija)
unusual hair loss or thinning (alopecia)
neobičajno izpadanje ali tanjšanje las (alopecija)
Unusual hair loss or thinning.
neobičajno izpadanje ali tanjšanje las,
unusual heart beat, sudden unexplained death, heart attack;
nenavaden srčni utrip, nenadna nepojasnjena smrt, srčni infarkt;
unusual heart rhythm (sinus arrhythmia and first-degree arterioventricular block)
nenavaden srčni ritem (sinusna aritmija in atrioventrikularni blok prve stopnje),
unusual heartbeat, sudden unexplained death, heart attack
nenavaden srčni utrip, nenadna nepojasnjena smrt, srčni infarkt,
unusual increased or altered sensitivity to touch
nenavadno povečana ali spremenjena občutljivost za dotik
unusual increased or altered sensitivity to touch’
nenavadno povečana ali spremenjena občutljivost za dotik
Unusual laboratory test results on liver function
težavno požiranje, neobičajni laboratorijski izvidi preiskave jetrnega delovanja.
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the
nenavadne zgibke (pogost neželeni učinek, ki lahko prizadene do 1 od 10 bolnikov), posebno v
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face
nenavadne zgibke (pogost neželeni učinek, ki lahko prizadene do 1 od 10 bolnikov), posebno v mišicah obraza ali jezika;
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
nenavadne gibe (pogost neželeni učinek, ki lahko prizadene do 1 od 10 bolnikov), predvsem obraza ali jezika; krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo oteklino, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
nenavadne zgibke (pogost neželeni učinek, ki lahko prizadene do 1 od 10 bolnikov), posebno v mišicah obraza ali jezika; krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
nenavadne zgibke (pogost neželeni učinek, ki se lahko pojavi pri manj kot 1od 10 bolnikov), posebno mišic obraza ali jezika; krvne strdke v venah (občasen neželeni učinek, ki se lahko pojavi pri manj kot 1 od 100 bolnikov) posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino nog), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; blood clots in the veins (an uncommon side effect that may affect up to 1in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
nenavadne zgibke (pogost neželeni učinek, ki se lahko pojavi pri največ 1 od 10 bolnikov), posebno v mišicah obraza ali jezika; krvne strdke v venah (občasen neželeni učinek, ki se lahko pojavi pri največ 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
unusual movement mainly of the face or tongue, since your doctor may want to lower your dose. if you have symptoms such as swelling, pain, and redness in the leg, because this may mean you have a blood clot, which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
neobičajne gibe, posebej v mišicah obraza ali jezika, saj bo morda vaš zdravnik želel zmanjšati odmerek; simptome, kot so otekanje, bolečina in pordelost kože na nogah, saj so lahko ti znak prisotnosti krvnih strdkov, ki lahko po krvnih žilah potujejo v pljuča in povzročijo bolečine v prsnem košu in težko dihanje.
Unusual movements (dyskinesias).
nenavadne gibe (diskinezijo),
Unusual movements(dyskinesias)
nenavadne gibe (diskinezijo),
Unusual noises in the chest (your doctor would hear this when listening to your lungs with a stethoscope)
neobičajni šumi v prsnem košu (sliši jih vaš zdravnik, ko pljuča posluša s stetoskopom),
unusual or irregular vaginal bleeding, heavy/prolonged periods premenstrual syndrome, vaginal irritation or discharge, lesser or greater sex drive
neobičajna ali neredna krvavitev iz nožnice, močne/podaljšane menstruacije, predmenstrualni sindrom, draženje ali izcedek iz nožnice, šibkejši ali močnejši spolni nagon
unusual sensation in eye, red eye, sensitivity to light
nenormalen občutek v očesu, rdeče oči, občutljivost oči na svetlobo
Unusual sensation of pins and needles, numbness or weakness of the arms and legs
zbadanje, ščegetanje, gomazenje, odrevenelost ali oslabelost rok in nog,
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
nenavadna zaspanost ali utrujenost sladkast zadah, sladek ali kovinski okus v ustih ali spremenjen vonj seča ali znoja
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
neobičajna zaspanost ali utrujenost sladek vonj izdihanega zraka, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja.
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
neobičajna zaspanost ali utrujenost sladek zadah, sladek ali kovinski okus v ustih ali drugačen vonj urina ali znoja.
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
neobičajna zaspanost ali utrujenost sladkast zadah, sladek ali kovinski okus v ustih ali drugačen vonj urina ali znoja.
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
neobičajna zaspanost ali utrujenost sladkast zadah, sladek ali kovinski okus v ustih ali spremenjen vonj seča ali znoja
unusual sleepiness or tiredness a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
neobičajna zaspanost ali utrujenost, sladek vonj izdihanega zraka, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja.
unusual taste in the mouth
nenavaden okus v ustih
unusual thirst
neobičajno žejo
Unusual tingling, weakness or pain in your hands or feet as these may indicate problems with your nerves (peripheral neuropathy).
To kaže na težave z živci (periferna nevropatija).
unusual tiredness
nenavadna utrujenost,
unusual tiredness or fever
nenavadna utrujenost ali povišana telesna temperatura,
unusual tiredness,
neobičajna utrujenost,
Unusual weakness
neobičajna oslabelost
Unusual weakness
neobičajna oslabelost,
unusual weakness
neobičajna šibkost
unusual weakness ● yellowing of the skin and/or eyes increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium change in the way the heart beats
neobičajna šibkost ● rumeno obarvanje kože in/ali oči povečana občutljivost kože za sonce, tudi če gre za indirektno izpostavljenost soncu (čez oblake, meglo) in UV (ultravijolično) svetlobo, na primer UV svetlobo v solariju. sprememba v načinu bitja srca
unusual weakness,
neobičajna šibkost,
unusual wheezing, or difficulty in breathing
neobičajno sopenje ali težko dihanje,
unusually low heart rate, feeling very warm (hot flushes),
neobičajno počasen srčni utrip, občutek vročine (vročinski oblivi)
Unusually slow movements or movements you cannot control
Neobičajno počasni gibi ali nehoteni gibi
Unvaccinated infants 6 months to 11 months of age should receive two injections followed by a third injection (booster).
Necepljeni dojenčki, stari od 6 do 11 mesecev, morajo prejeti dve injekciji cepiva, kateri sledi še tretja (poživitveni odmerek).
Unvaccinated infants, 6 months to 11 months
necepljeni dojenčki, od 6 do 11 mesecev
Unwilling
Niso voljni
Unwrap the 21 gauge needle and fix it to the syringe from which you removed the tip cap before.
Odvijte iglo velikosti 21 in jo pritrdite na brizgo, s konice katere ste pred tem sneli pokrov.
Unwrap the 30 gauge needle and connect it to the syringe.
Iglo velikosti 30 odvijte in jo nataknite na brizgo.
Unwrap the needle to expose the connection port.
Odstranite ovoj z igle, da razkrijete pritrditveni del.
Unwrap the needle with the grey mark on it.
Odvijte iglo, ki ima sivo oznako.
Unwrap the needle with the yellow mark on it.
Odvijte iglo, ki ima rumeno oznako.
UOther medicinal productsU
Druga zdravila
Up to 0.05 mg/kg bodyweight given as a daily subcutaneous injection.
Do 0,05 mg/kg telesne mase v vsakodnevni subkutani injekciji.
Up to 1 in 10 people taking Tafinlar may develop a different type of skin cancer called cutaneous squamous cell carcinoma (cuSCC).
Pri do 1 od 10 bolnikov, ki jemljejo zdravilo Tafinlar, se lahko pojavi drugačna vrsta kožnega raka, ki ga imenujemo ploščatocelični karcinom kože (cuSCC – Cutaneous Squamous Cell Carcinoma).
Up to 10 times the recommended dose was tolerated in cats with no evidence of adverse effects or undesirable clinical signs.
Pri aplikaciji desetkratnega terapevtskega odmerka pri mačkah ni bilo neželenih kliničnih znakov.
Up to 12 days from the date of manufacture.
Do 12 dni od datuma izdelave.
Up to 14 days
največ 14 dni
Up to 2 additional injections may be given within 24 hours.
V roku 24 ur se lahko dasta 2 dodatni injekciji.
Up to 20 mg in 24 hours may be given.
V 24 urah se sme dati do 20 mg.
Up to 20, 37 and 20 metabolites were detected in plasma, urine and faeces respectively, the majority of them representing < 1% of the dosed material.
V plazmi so odkrili do 20 presnovkov, v urinu do 37 in v blatu do 20; večina od teh je predstavljala < 1 % uporabljenega zdravila.
Up to 28 mg/kg/day
do 28 mg/kg/dan
up to 36 kg for the 55 ml bottle
do 36 kg za 55-mililitrsko stekleničko;
Up to 4 injection sites can be used simultaneously, provided that the maximum infusion rate for all sites combined does not exceed 50 ml/hour.
Hkrati se lahko uporabijo do 4 mesta injiciranja pod pogojem, da največja hitrost injiciranja za vsa mesta skupaj ne preseže 50 ml/uro.
Up to 4 mL
do 4 ml
Up to 40 mg/kg/day
do 40 mg/kg/dan
up to 40 ml
do 40 ml
Up to 45 hours subsequent
Nadaljnja do 45 ur intravenska infuzija
Up to 50% of the elderly subjects immunised with H5N1 vaccine combined with MF59C were seroprotected at six months.
Do 50 % starejših oseb, imuniziranih s cepivom proti H5N1 z dodanim MF59C, je bilo v šestem mesecu serozaščitenih.
Up to 6 additional cases per 100,000 infants have been observed in the US and Australia against a background incidence of 33 to 101 per 100,000 infants (less than one year of age) per year, respectively.
V ZDA in Avstraliji so ugotovili do 6 dodatnih primerov na 100.000 dojenčkov v primerjavi z osnovno incidenco od 33 do 101 na 100.000 dojenčkov (mlajših od enega leta starosti) na leto.
Up to 71% of patients lived for at least 12 months after start of their treatment compared with 58% of patients on ipilimumab.
Po začetku zdravljenja je 71 % bolnikov živelo vsaj 12 mesecev, v skupini z ipilimumabom pa 58 % bolnikov.
Up to 8 cycles of this combination therapy can be administered as long as patients have not progressed and tolerate treatment.
Bolniki, pri katerih bolezen ne napreduje in zdravljenje dobro prenašajo, lahko prejmejo največ 8 krogov kombiniranega zdravljenja.
Up to four vials containing Savene concentrate may be necessary to obtain the required dose for the patient.
Da dosežete potreben odmerek za bolnika, boste morda potrebovali do štiri viale koncentrata zdravila Savene.
Up to now there is no experience of acute poisoning with Iasibon concentrate for solution for infusion.
Ni poročil o primerih akutnega prevelikega odmerjanja s koncentratom za raztopino za infundiranje Iasibon.
Up to Week 96, the development of one or more primary elvitegravir, emtricitabine, or tenofovir alafenamide resistance-associated mutations was observed in HIV-1 isolates from 10 of 19 patients with evaluable genotypic data from paired baseline and Genvoya treatment-failure isolates (10 of 866 patients [1.2%]) compared with 8 of 16 treatment-failure isolates from patients in the E/C/F/TDF treatment group (8 of 867 patients [0.9%]).
Do 96. tedna so opazili razvoj ene ali več primarnih mutacij, povezanih z rezistenco na elvitegravir, emtricitabin ali alafenamidtenofovirat, pri izolatih HIV-1 pri 10 od 19 bolnikov, pri katerih je bilo mogoče oceniti genotipske podatke parov izolatov ob začetku in izolatov neuspešnega zdravljenja z zdravilom Genvoya (10 od 866 bolnikov [1,2 %]) v primerjavi z 8 od 16 izolatov neuspešnega zdravljenja pri bolnikih v skupini, zdravljeni z E/C/F/TDF (8 od 867 bolnikov [0,9 %]).
Up to Year 1
do 1. leta
Up to Year 3*
do 3. leta
Up to Year 3, there were no reports of anaphylaxis or hypersensitivity related to the medicinal product.
Do 3. leta zdravljenja niso poročali o pojavu anafilaksije ali preobčutljivosti na zdravilo.
up your syringe and slowly inject the solvent into the vial of Luveris.
Luveris, vzemite brizgo in počasi injicirajte vehikel v vialo z zdravilom Luveris.
Up-regulation of VEGF is associated with the breakdown of the blood retina barrier, increased vascular permeability retinal oedema, and neovascularisation complications.
Povečano sproščanje VEGF je povezano z razpadanjem krvno-mrežnične pregrade, povečanjem prepustnosti žil, edemom mrežnice in zapleti neovaskularizacije.
Up-to- date information should be provided on the source countries of origin of the animals supplying the milk for preparation of the Tryptose from BD Biosciences and for the preparation of the casein, and lactose where appropriate, for manufacture of the NZ-Amines purchased from Quest/Kerry.
Navedeni morajo biti posodobljeni podatki o državah izvora za živali, ki služijo kot vir mleka za pripravo triptoze iz BD Biosciences in za pripravo kazeina ter laktoze, kadar je primerno, za izdelavo NZ-aminov, kupljenih pri Quest/Kerry.
UPackage size
UVelikost pakiranja
UPackaging
UOvojnina
UPaediatric population
Pediatrična populacija
UpCard 0.75 mg tablets for dogs UpCard 3 mg tablets for dogs UpCard 7.5 mg tablets for dogs UpCard 18 mg tablets for dogs
0,75 mg tablete za pse UpCard 3 mg tablete za pse UpCard 7,5 mg tablete za pse UpCard 18 mg tablete za pse UpCard
UpCard 18 mg tablets for dogs 18 mg of torasemide
UpCard 18 mg tablete za pse 18 mg torasemida
UpCard 7.5 mg tablets for dogs 7.5 mg of torasemide
UpCard 7,5 mg tablete za pse 7,5 mg torasemida
Updated Analysis (62% OS
Posodobljena analiza (z 62
Updated efficacy data in subgroups comparing 2 vs 10 mg/kg Q3W from the P002 final analysis.
Dopolnjene podatke o varnosti v podskupinah za primerjavo 2 proti 10 mg/kg vsake 3 tedne iz končne analize P002
Updated implementation plan should be submitted no later than 30 June 2016.
Posodobljen implementacijski plan mora biti predan najkasneje do 30. junija 2016.
Updated Survival Analysis
Dodatna analiza preživetja
Updated survival analysis
Posodobljena analiza preživetja
Updates on PFS, OS and duration of response for patients with or without 17p deletion/TP53 mutation and the whole population should be submitted.
Predložiti je treba posodobitve glede PFS, OS in trajanje odziva za bolnike z delecijo 17p in/ali mutacijo TP53 ali brez njiju in za celo populacijo.
Updates on safety and efficacy results including overall survival and updates of the analyses of subjects with baseline lymphopenia, should be submitted.
Predložiti je treba posodobljene rezultate o varnosti in učinkovitosti, vključno s celokupnim preživetjem in posodobljene analize oseb z limfopenijo ob izhodišču.
uperficial punctate keratitis, corneal erosion, ocular burning, ocular irritation, allergic conjunctivitis, blepharitis, worsening of visual acuity, asthenopia, conjunctival oedema, foreign body sensation, ocular dryness, eye pain, photophobia, tearing, eye discharge, visual disturbance/blurred vision, increased iris pigmentation, eyelash darkening, eyelid erythema, eyelid pruritus
površinski točkasti keratitis, erozija roženice, pekoče oči, draženje očesa, alergijski konjunktivitis, blefaritis, slabšanje ostrine vida, astenopija, konjunktivni edem, občutek tujka v očesu, suhe oči, bolečine v očeh, fotofobija, solzenje, očesni izcedek, motnje vida/zamegljen vid, povečana pigmentacija irisa, temnenje trepalnic, eritem vek, pruritus vek
UPharmacokinetics in special populations
Farmakokinetika pri posebnih skupinah bolnikov
Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returns to pre-treatment values over a period of several days without evidence of rebound hypertension.
Po nenadnem prenehanju zdravljenja s telmisartanom se krvni tlak v nekaj dneh postopoma zviša na vrednosti pred zdravljenjem, brez znakov preobratne hipertenzije.
Upon administration of MabThera at a dose of 375 mg/m2 as an intravenous infusion at weekly intervals for 8 doses to 37 patients with NHL, the mean Cmax increased with each successive infusion, spanning from a mean of 243 µg/mL (range, 16 – 582 µg/mL) after the first infusion to 550 µg/mL (range, 171 – 1177 µg/mL) after the eighth infusion.
Pri 37 bolnikih z ne-Hodgkinovim limfomom, ki so prejeli 375 mg/m2 zdravila MabThera z intravensko infuzijo v osmih odmerkih enkrat na teden, se je povprečna Cmax povečala z vsako naslednjo infuzijo, tako da se je iz povprečne vrednosti 243 µg/ml (od 16 do 582 µg/ml) po prvi infuziji povečala na 550 µg/ml (171 do 1177 µg/ml) po osmi infuziji.
Upon binding to HER2, trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in release of DM1-containing cytotoxic catabolites (primarily lysine-MCC-DM1).
Po vezavi na HER2 je trastuzumab emtanzin podvržen receptorsko posredovani internalizaciji in nato lizosomski razgradnji, ki sprosti citotoksične katabolite, ki vsebujejo DM1 (v prvi vrsti lizin-MCC- DM1).
Upon co-administration with ritonavir- boosted lopinavir, the plasma concentrations of intravenous midazolam increased by 5.4-fold, associated with a similar increase in terminal half-life.
Ob sočasnem dajanju z ritonavirom ojačanega lopinavira in midazolama, ki ga apliciramo intravensko, se je plazemska koncentracija midazolama povečala za 5,4-krat, kar je bilo povezano s podobnim povečanjem njegove končne razpolovne dobe.
Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected.
Po sočasnem dajanju z efavirenzom, testnim zmernim induktorjem CYP3A, ni bilo značilnega vpliva na izpostavljenost alafenamidtenofoviratu.
Upon complete dissolution, the reconstituted product may be drawn up into a sterile disposable syringe.
Po popolni raztopitvi lahko rekonstituirano zdravilo napolnimo v sterilno injekcijsko brizgo za enkratno uporabo.
Upon complete withdrawal of the needle, apply gentle pressure at the injection site.
Po popolnem izvleku igle nežno pritisnite na mesto injiciranja.
Upon completion of both studies, 383 patients enrolled in an open-label extension study, in which 40 mg Humira was administered every other week.
Po koncu obeh študij so 383 bolnikov vključili v odprto nadaljevalno študijo, med katero so bolniki dobivali 40 mg zdravila Humira vsak drugi teden.